Eli Lilly and Company $LLY Shares Sold by Larson Financial Group LLC

Key Points

• Larson Financial Group LLC trimmed its Eli Lilly stake by 16.4% in the fourth quarter, selling 2,755 shares and leaving it with 14,006 shares valued at about $15.05 million.
• Wall Street remains broadly positive on LLY, with an average analyst rating of “Moderate Buy” and an average price target of $1,218.33. Recent reports from firms like Deutsche Bank, TD Cowen, and Wolfe Research mostly reaffirmed bullish outlooks.
• Eli Lilly continues to post strong operating results, reporting $8.55 EPS and $19.8 billion in quarterly revenue, both well above expectations. Revenue rose 55.5% year over year, and the company reiterated FY2026 EPS guidance of 35.5 to 37.0.

Larson Financial Group LLC cut its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 16.4% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 14,006 shares of the company's stock after selling 2,755 shares during the quarter. Larson Financial Group LLC's holdings in Eli Lilly and Company were worth $15,052,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. 10Elms LLP grew its position in shares of Eli Lilly and Company by 33.3% during the third quarter. 10Elms LLP now owns 40 shares of the company's stock worth $31,000 after buying an additional 10 shares in the last quarter. M.E. Allison & CO. Inc. grew its position in shares of Eli Lilly and Company by 0.7% during the fourth quarter. M.E. Allison & CO. Inc. now owns 1,477 shares of the company's stock worth $1,587,000 after buying an additional 10 shares in the last quarter. Tanager Wealth Management LLP grew its position in shares of Eli Lilly and Company by 2.6% during the fourth quarter. Tanager Wealth Management LLP now owns 395 shares of the company's stock worth $424,000 after buying an additional 10 shares in the last quarter. Morey & Quinn Wealth Partners LLC grew its position in shares of Eli Lilly and Company by 1.5% during the fourth quarter. Morey & Quinn Wealth Partners LLC now owns 661 shares of the company's stock worth $710,000 after buying an additional 10 shares in the last quarter. Finally, Wealthspan Partners LLC grew its position in shares of Eli Lilly and Company by 0.5% during the fourth quarter. Wealthspan Partners LLC now owns 2,110 shares of the company's stock worth $2,268,000 after buying an additional 10 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on LLY. Deutsche Bank Aktiengesellschaft reaffirmed a "buy" rating and issued a $1,285.00 price target on shares of Eli Lilly and Company in a report on Friday, March 6th. CICC Research upped their price target on Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the company a "neutral" rating in a report on Wednesday, February 11th. TD Cowen upped their price target on Eli Lilly and Company from $960.00 to $1,250.00 and gave the company a "buy" rating in a report on Thursday, January 29th. Wolfe Research reaffirmed an "outperform" rating and issued a $1,325.00 price target on shares of Eli Lilly and Company in a report on Monday, May 4th. Finally, Sanford C. Bernstein reaffirmed an "outperform" rating on shares of Eli Lilly and Company in a report on Tuesday, March 10th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $1,218.33.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Investor enthusiasm remains supported by Eli Lilly’s powerful obesity and diabetes drug franchise, with articles highlighting surging Mounjaro/Zepbound demand and expectations for continued growth. Article Title
• Positive Sentiment: Recent business momentum is still very strong, with second-quarter-level commentary pointing to major sales growth and raised revenue expectations that reinforce the company’s long-term earnings power. Article Title
• Neutral Sentiment: Eli Lilly said it will participate in Bernstein’s Strategic Decisions Conference on May 28, which could give investors updated strategic and pipeline commentary, but the event itself is not a major near-term catalyst. Article Title
• Neutral Sentiment: Healthcare stocks were broadly stronger late Monday, which may have helped support LLY alongside the sector, but this looks like a market-wide move rather than a company-specific driver. Article Title
• Negative Sentiment: The Supreme Court’s refusal to hear Lilly’s challenge keeps a Medicaid fraud verdict alive, reinforcing litigation risk and potentially raising concerns about future government-rebate disputes and legal expenses. Article Title
• Negative Sentiment: Competition in obesity treatment remains intense, with Citi data suggesting Novo Nordisk’s Wegovy pill still has a strong prescription lead over Lilly’s rival programs, which could temper near-term excitement around Lilly’s market share gains. Article Title

Eli Lilly and Company Stock Performance

Shares of LLY opened at $988.76 on Tuesday. The stock has a 50 day moving average price of $940.00 and a 200 day moving average price of $999.39. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. The company has a market capitalization of $931.15 billion, a price-to-earnings ratio of 35.12, a price-to-earnings-growth ratio of 1.09 and a beta of 0.48. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,133.95.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, beating the consensus estimate of $6.97 by $1.58. The business had revenue of $19.80 billion during the quarter, compared to the consensus estimate of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The company's revenue was up 55.5% compared to the same quarter last year. During the same period in the prior year, the company earned $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Research analysts predict that Eli Lilly and Company will post 35.82 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend is Friday, May 15th. Eli Lilly and Company's dividend payout ratio is presently 24.58%.

Eli Lilly and Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.